Conduit Pharmaceuticals Inc
CDTTW0.009USD
0.000
Market hours （ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Conduit Pharmaceuticals Inc Company
Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
Company Info
Ticker SymbolCDTTW
Company nameConduit Pharmaceuticals Inc
IPO dateFeb 03, 2022
Founded at2021
CEODr. Andrew Regan
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address4851 Tamiami Trail North
CityNAPLES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code34103
Phone16464919132
Websitehttps://www.conduitpharma.com/
Ticker SymbolCDTTW
IPO dateFeb 03, 2022
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
--
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
--
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
37
8.01M
0.00%
-1.58M
2024Q4
39
8.02M
0.00%
-2.09M
2024Q3
42
9.11M
0.00%
-1.29M
2024Q2
41
8.93M
0.00%
-1.72M
2024Q1
41
8.90M
0.00%
-1.63M
2023Q4
41
8.79M
0.00%
-2.17M
2023Q3
41
9.69M
0.00%
-1.01M
2023Q2
39
9.49M
0.00%
-1.33M
2023Q1
39
9.60M
0.00%
-735.84K
2022Q4
33
9.57M
0.00%
+190.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Heights Capital Management, Inc.
78.96K
0%
--
--
Dec 31, 2024
Polar Asset Management Partners Inc.
950.00K
0%
--
--
Dec 31, 2024
Saba Capital Management, L.P.
765.00K
0%
--
--
Dec 31, 2024
MMCAP Asset Management
700.00K
0%
--
--
Dec 31, 2024
Clear Street LLC
409.73K
0%
+200.00
+0.05%
Dec 31, 2024
Decagon Asset Management LLP
400.00K
0%
+400.00K
--
Dec 31, 2024
D. E. Shaw & Co., L.P.
375.00K
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
